https://profiles.umassmed.edu/display/26883309
Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. | Profiles...
randomized clinical trialpostpartum depressioneffectzuranolonevs
https://www.astralcodexten.com/p/zounds-its-zulresso-and-zuranolone/comments
Comments - Zounds! It's Zulresso and Zuranolone!
How excited should we be about the latest class of antidepressants?
commentszuranolone
https://researchworks.creighton.edu/esploro/outputs/journalArticle/Zuranolone-for-the-Treatment-of-Adults/991006241103002656
Zuranolone for the Treatment of Adults With Major Depressive Disorder - Creighton University
Jul 1, 2024 - Zuranolone for the Treatment of Adults With Major Depressive Disorder - Creighton University - Journal article
treatment of adultsmajor depressive disorderfor thecreighton universityzuranolone
https://www.fiercebiotech.com/biotech/sage-tweaks-primary-endpoint-for-zuranolone-depression-trial-leaving-key-durability
Sage tweaks primary endpoint for zuranolone depression trial, leaving key durability question...
Nov 2, 2021 - Sage Therapeutics has slightly tweaked the primary endpoint for a phase 3 trial of the Biogen-partnered depression drug zuranolone, a move analysts say is...
primary endpointsagetweakszuranolonedepression
https://www.biospace.com/sage-therapeutics-and-biogen-announce-positive-one-year-zuranolone-50-mg-data-in-the-ongoing-open-label-shoreline-study-in-patients-with-mdd
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing...
Dec 1, 2021 - In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the...
one yearsagetherapeuticsbiogenannounce
https://www.pharmafocusasia.com/technotrends/biogen-and-sage-therapeutics-introduce-first-of-its-kind-zurzuvae-for-postpartum-depression
Zuranolone for Postpartum Depression | Technology trends in Pharma
This new treatment seems to be a significant step forward in addressing the needs of women who suffer from this condition.
postpartum depressiontechnology trendszuranolonepharma